GlassScriptPhysician profile
Christina S Thury
NPI 1518681386
$1,287.76
in general payments reported to CMS, 2019-2025
29 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $540 · 2024: $371 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.12 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $157.68 | 2023-2024 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $114.58 | 2025 | Nuplazid |
| Genentech, INC. | $96.94 | 2025 | Ocrevus |
| Pfizer INC. | $45.66 | 2024-2025 | |
| Harmony Biosciences LLC | $44.60 | 2023-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $43.20 | 2023-2024 | Hyqvia |
| Impel Pharmaceuticals INC. | $42.90 | 2023 | Trudhesa |
| Argenx US, INC. | $37.24 | 2023-2024 | |
| Tg Therapeutics, INC. | $34.14 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $34.09 | 2023 | Relyvrio |
| Ucb, INC. | $33.77 | 2023 | |
| Tanabe Pharma America, INC. | $31.34 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $31.31 | 2023 | Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $31.17 | 2023-2025 | Lumryz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $31.13 | 2023 | Hizentra |
| Celgene Corporation | $30.79 | 2023-2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $28.58 | 2023 | Fycompa |
| Jazz Pharmaceuticals INC. | $28.17 | 2024 | |
| Genentech USA, INC. | $27.95 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $24.99 | 2023 | Valtoco |
| Sk Life Science, INC. | $20.31 | 2024 | |
| Axsome Therapeutics, INC. | $20.22 | 2025 | Symbravo |
| Emd Serono, INC. | $19.08 | 2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $17.83 | 2023 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $15.21 | 2023 | Amvuttra |
| Eisai INC. | $15.00 | 2023 | |
| Baxter Healthcare | $14.86 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Bio Products Laboratory USA, INC. | $12.90 | 2023 | Gammaplex, Coagadex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Thury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.